Storia in 2 fonti

Capricor Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Capricor (CAPR)

Raccontata da

benzinga.com

morningstar.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

morningstar.comStai leggendo1 mese fa

Capricor Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Capricor…

Capricor stock collapsed 60-70% after FDA briefing documents contradicted the company's May claim that Deramiocel slowed cardiac decline 91% versus placebo. The incident highlights governance risk when clinical trial claims lack pre-specified statistical validation.

originale

benzinga.com1 mese fa

Capricor Therapeutics Shares Dive Before Key Review as FDA Panel Challenges Data - Capricor Therapeutics

Capricor stock falls 61% as FDA challenges Deramiocel efficacy; Phase 3 DMD trial missed primary endpoint, cardiac data show no benefit. Signal for biotech acquirers: late-stage efficacy gaps elevate regulatory risk, erode valuations, tighten clinical M&A discipline.

Capricor Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Capricor (CAPR)

Confronto fonti

Capricor Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Capricor…

Capricor Therapeutics Shares Dive Before Key Review as FDA Panel Challenges Data - Capricor Therapeutics

Timeline cronologica

Capricor Therapeutics Shares Dive Before Key Review as FDA Panel Challenges Data - Capricor Therapeutics

Securities Fraud Investigation Into Capricor Therapeutics, Inc. (CAPR) Announced Following Critical FDA Review Ahead of Advisory Committee…

Rosen Law Firm Encourages Capricor Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – CAPR

Securities Fraud Investigation Into Capricor Therapeutics, Inc. (CAPR) Announced Following Critical FDA Review Ahead of Advisory Committee…

Capricor Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Capricor (CAPR)

Securities Fraud Investigation Into Capricor Therapeutics, Inc. (CAPR) Announced Concerning FDA Review And Advisory Committee Meeting -…

Rosen Law Firm Encourages Capricor Therapeutics Inc. Investors to Inquire About Securities Class Action Investigation - CAPR

Capricor Stock Tumbles After FDA Panel Rejects Evidence for Duchenne Cell Therapy - Capricor Therapeutics

Capricor Therapeutics Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel

CAPR Stock Drop Alert: Capricor Therapeutics Stock Plummets Over 64% After FDA Briefing Documents Raise Concerns, Triggering Securities…

CAPR Alert: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors Urged to Contact Hagens Berman; Investigation Opened Following Massive…

CAPR CLASS ACTION NOTICE: Glancy Prongay Wolke & Rotter LLP Files Securities Fraud Lawsuit on Behalf of Capricor Therapeutics, Inc.

CAPR CLASS ACTION NOTICE: The Law Offices of Frank R. Cruz Files Securities Fraud Lawsuit Against Capricor Therapeutics, Inc.

Law Offices of Howard G. Smith Encourages Capricor Therapeutics, Inc. (CAPR) Shareholders To Inquire About Securities Fraud Class Action

CAPR Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Capricor (CAPR)

Shareholder Alert - Robbins LLP Informs Investors of the Capricor Therapeutics, Inc. Class Action Lawsuit

Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn…

CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law